These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23190347)

  • 1. Axitinib: in advanced, treatment-experienced renal cell carcinoma.
    Yang LP; McKeage K
    Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
    Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
    Bracarda S; Castellano D; Procopio G; Sepúlveda JM; Sisani M; Verzoni E; Schmidinger M
    Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
    Cella D; Escudier B; Rini B; Chen C; Bhattacharyya H; Tarazi J; Rosbrook B; Kim S; Motzer R
    Br J Cancer; 2013 Apr; 108(8):1571-8. PubMed ID: 23579211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
    Hutson TE; Al-Shukri S; Stus VP; Lipatov ON; Shparyk Y; Bair AH; Rosbrook B; Andrews GI; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Feb; 15(1):72-76. PubMed ID: 27498023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib: a review in advanced renal cell carcinoma.
    Keating GM
    Drugs; 2015 Nov; 75(16):1903-13. PubMed ID: 26487541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
    Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
    Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
    Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
    Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
    Larkin J; Fishman M; Wood L; Negrier S; Olivier K; Pyle L; Gorbunova V; Jonasch E; Andrews L; Staehler M
    Am J Clin Oncol; 2014 Aug; 37(4):397-403. PubMed ID: 23357974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
    Qin S; Zhang S
    Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
    [No Abstract]   [Full Text] [Related]  

  • 16. Axitinib for renal cell carcinoma.
    Sonpavde G; Hutson TE; Rini BI
    Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
    Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
    Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib for the management of metastatic renal cell carcinoma.
    Escudier B; Gore M
    Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib-induced acute pancreatitis: a case report.
    Péron J; Khenifer S; Potier V; Vitry T; Pasquet F; Rassat R; Pavic M
    Anticancer Drugs; 2014 Apr; 25(4):478-9. PubMed ID: 24398664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible posterior leukoencephalopathy syndrome induced by axitinib.
    Levy A; Benmoussa L; Ammari S; Albiges L; Escudier B
    Clin Genitourin Cancer; 2014 Feb; 12(1):e33-4. PubMed ID: 24135633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.